YIELD10 BIOSCIENCE INC (YTEN)
US98585K8541 - Common Stock
YTEN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 581 industry peers in the Biotechnology industry. YTEN has a bad profitability rating. Also its financial health evaluation is rather negative. YTEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year YTEN has reported negative net income.
In the past year YTEN has reported a negative cash flow from operations.
YTEN had negative earnings in each of the past 5 years.
YTEN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -370.00%, YTEN is not doing good in the industry: 96.74% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -370% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-197.19%
ROA(5y)-147.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for YTEN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
YTEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for YTEN has been reduced compared to 1 year ago.
YTEN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, YTEN has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -157.47, we must say that YTEN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -157.47, YTEN is doing worse than 98.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -157.47 |
ROIC/WACCN/A
WACC9.13%
2.3 Liquidity
YTEN has a Current Ratio of 0.29. This is a bad value and indicates that YTEN is not financially healthy enough and could expect problems in meeting its short term obligations.
YTEN has a worse Current ratio (0.29) than 96.57% of its industry peers.
A Quick Ratio of 0.29 indicates that YTEN may have some problems paying its short term obligations.
The Quick ratio of YTEN (0.29) is worse than 96.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.29 | ||
| Quick Ratio | 0.29 |
3. Growth
3.1 Past
YTEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1075.36%.
YTEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.67%.
The Revenue for YTEN have been decreasing by -36.03% on average. This is quite bad
EPS 1Y (TTM)-1075.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-867.16%
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y-36.03%
Sales Q2Q%-100%
3.2 Future
YTEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.95% yearly.
The Revenue is expected to grow by 288.42% on average over the next years. This is a very strong growth
EPS Next Y97.63%
EPS Next 2Y40.47%
EPS Next 3Y25.9%
EPS Next 5Y14.95%
Revenue Next Year2712.5%
Revenue Next 2Y607.11%
Revenue Next 3Y594.08%
Revenue Next 5Y288.42%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for YTEN. In the last year negative earnings were reported.
Also next year YTEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
YTEN's earnings are expected to grow with 25.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.9%
5. Dividend
5.1 Amount
YTEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
YIELD10 BIOSCIENCE INC
NASDAQ:YTEN (5/15/2024, 7:18:42 PM)
After market: 2.89 +0.01 (+0.35%)2.88
-2.38 (-45.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap44.35M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -370% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.29 | ||
| Quick Ratio | 0.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-1075.36%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y97.63%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y